Business description: Natera, Inc.

Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.

Number of employees: 6,138

Sales by Activity: Natera, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

Development and Commercialization of Molecular Testing Services

625M 820M 1.08B 1.7B 2.31B

Geographical breakdown of sales: Natera, Inc.

Fiscal Period: December 2021 (USD) 2022 (USD) 2023 (USD) 2024 (USD) 2025 (USD)

United States

591M 786M 1.05B 1.66B 2.26B

Europe, Middle East, India, Africa

20.43M 16.64M 22.81M 23.88M 24.48M

Americas, Excluding U.S.

4.05M 3.7M 4.91M 6.62M 9.35M

Asia Pacific and Other

10.14M 14.03M 7.22M 8.66M 8.01M

Executive Committee: Natera, Inc.

Manager TitleAgeSince
Chief Executive Officer 47 01/01/2019
President 46 31/08/2023
Director of Finance/CFO 45 31/01/2017
Compliance Officer - 31/07/2017
Chief Tech/Sci/R&D Officer - 31/12/2022

Composition of the Board of Directors: Natera, Inc.

Director TitleAgeSince
Chairman 53 30/04/2015
Director/Board Member 53 31/12/2006
Director/Board Member 47 01/01/2019
Director/Board Member 78 31/01/2017
Director/Board Member 52 31/12/2006
Director/Board Member 69 14/03/2017
Director/Board Member 71 24/07/2018
Director/Board Member 55 14/08/2019
Director/Board Member 74 01/03/2023
Director/Board Member 67 25/03/2026

Shareholders: Natera, Inc.

NameStocks%Valuation
JPMorgan Investment Management, Inc.
9.347 %
13,386,667 9.347 % 3 634 M $
T. Rowe Price International Ltd.
8.508 %
12,184,876 8.508 % 3 308 M $
BlackRock Advisors LLC
6.282 %
8,997,345 6.282 % 2 442 M $
Vanguard Capital Management LLC
4.195 %
6,008,496 4.195 % 1 631 M $
Vanguard Portfolio Management LLC
3.941 %
5,644,695 3.941 % 1 532 M $

Company details: Natera, Inc.

Natera, Inc.

Building A, 13011 McCallen Pass

78753, Austin

+

http://www.natera.com
address Natera, Inc.(NTRA)

Medical & Diagnostic Laboratories

Change 5-day change 1-year change 3-year change Capi.($)
+1.73%+1.09%+85.10%+459.67% 39.72B
-1.34%-2.07%+10.72%+27.83% 22.3B
+1.21%+1.78%-20.31%-39.66% 7.43B
-2.18%-6.37%+10.73%+96.76% 4.83B
+0.20%+2.62%+15.73%+47.74% 2.99B
+5.94%+0.79%-19.04%+884.23% 1.96B
+1.90%+1.83%+110.14%-15.99% 1.89B
+3.85%+22.13%-3.31%-63.38% 1.92B
+3.37%+9.73%+34.98%-18.27% 1.85B
+0.61%+7.14%+29.29%+7.84% 1.77B
Average +1.53%+3.94%+25.40%+138.68% 8.67B
Weighted average by Cap. +0.78%+0.57%+44.41%+239.55%
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
277.37USD
Average target price
279.76USD
Spread / Average Target
+0.86%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NTRA Stock
  4. Company Natera, Inc.